Salted Ltd. Sets a New Standard for Hospital Functional Assessment with Smart Insole–Based Solutions

Q. Company Introduction

Salted Ltd. develops digital medical device solutions for gait and balance analysis based on smart insoles. It provides an integrated solution that quantitatively collects and analyzes patients’ movement data in clinical settings and supports its use in medical evaluation and treatment decision-making.

The flagship product, NEUROGAIT, is a digital functional assessment solution designed to enable hospitals and medical institutions to quickly and easily measure patients’ gait, balance, lower limb function, and fall risk. Its strength lies in its high clinical usability, as smart insoles, a dedicated application, result reports, and a cloud-based data management system are seamlessly integrated into a single system.

Salted is driving the digital transformation of functional assessment across various clinical fields—including orthopedics, neurosurgery, and rehabilitation medicine—based on its experience in Korean clinical settings and its data-driven technology. It has also steadily secured the regulatory approvals required for entry into domestic and international markets and is building a foundation for global expansion, including FDA registration.

Q. Product Description and Key Strengths

NEUROGAIT is a digital functional assessment solution that measures and analyzes patients’ gait and balance based on plantar pressure and movement data. Conventional gait and balance assessment equipment is typically expensive, requires significant installation space, and is often limited to specific types of tests. In contrast, NEUROGAIT addresses these limitations through a simple, wearable smart insole–based measurement approach, helping hospitals conduct functional assessments more efficiently.

In particular, NEUROGAIT enables a wide range of physical function assessments to be performed within a single solution, including gait tests (10mWT), balance tests (Romberg Test, OLST), lower limb strength tests (Sit-to-Stand), and Short Physical Performance Battery (SPPB). This is significant in that it enhances equipment efficiency and consistency in testing processes for hospitals and clinicians, while providing patients with a more convenient and structured assessment experience.

NEUROGAIT also has a strong advantage in terms of price competitiveness. Unlike conventional functional assessment equipment, which typically requires high upfront costs and significant space, NEUROGAIT offers a practical alternative that healthcare providers can adopt under more realistic conditions. In other words, NEUROGAIT is not just a measurement device, but a solution that simultaneously addresses the limitations of cost, space, and utility in the existing functional assessment market.

The measurement results are provided in the form of quantified reports, which can be extended for various purposes such as patient explanation, pre- and post-treatment comparison, progress monitoring, and clinical research. In particular, NEUROGAIT can be used to assess functional status and track changes in a wide range of patient groups, including those with knee and hip disorders, spinal conditions and post-surgical cases, neurological disorders such as Parkinson’s disease and peripheral neuropathy, as well as various rehabilitation patients, offering broad value across diverse clinical settings. 

Q. Future Export Strategy

Starting this year, Salted is actively accelerating its expansion into the global market. Its future export strategy goes beyond simple product sales, focusing on positioning NEUROGAIT as a solution that delivers tangible value to hospitals and patients through pre- and post-operative functional assessment across various clinical fields, including orthopedics, neurosurgery, and rehabilitation medicine.

In particular, NEUROGAIT’s ability to quantitatively assess functional recovery in patients with knee, hip, and spinal conditions and post-surgical cases, as well as to evaluate and track changes in patients with neurological disorders such as Parkinson’s disease and peripheral neuropathy, along with a wide range of rehabilitation patients, is a key competitive advantage. From the perspective of overseas healthcare providers, this makes it a practical and highly scalable solution applicable to diverse patient populations.

Salted has also been steadily securing the regulatory approvals required for global market entry, and plans to expand collaboration with global partners and buyers based on its readiness for overseas markets, including FDA registration.

Website: www.neurogait.ai